Blood pressure, vessels and drug intervention: “To help or at least to not harm” by Sudano, Isabella
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2012
Blood pressure, vessels and drug intervention: “To help or at least to not
harm”
Sudano, Isabella
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-77251
Originally published at:
Sudano, Isabella. Blood pressure, vessels and drug intervention: “To help or at least to not harm”. 2012,
University of Zurich, Faculty of Medicine.
HABILITATIONSSCHRIFT 
 
 
 
 
 
 
 
 
 
Blood pressure, vessels and drug intervention: 
“To help or at least to not harm” 
 
Dr. med Isabella Noll Sudano 
 
 
 
„Zur Erlangung der venia Legendi der Universität Zürich“ 
 
 
 
 
 
 
 
 
 
Zürich, den 07.03.2011 
 2 
Vorwort 
 
Die nachfolgend angeführten und beigelegt Originalarbeiten werden als 
kumulative Habilitationsschrift eingereicht. 
 
1. Sudano I, Virdis A, Taddei S, Spieker L, Corti R, Noll G, Salvetti A, Luscher 
TF. Chronic Treatment With Long-Acting Nifedipine Reduces Vasoconstriction 
to Endothelin-1 in Essential Hypertension. Hypertension 2007. 49: 285-290 
 
2. Flammer AJ*, Sudano I*, Hermann F, Gay S, Forster A, Neidhart M, 
Künzler P, Enseleit F, Périat D, Hermann M, Nussberger J, Lüscher TF, Corti 
R, Noll G, Ruschitzka F. Angiotensin converting enzyme Inhibition improves 
vascular function in rheumatoid arthritis. Circulation 2008. 29; 117(17):2262-
2269. * both author contribute equally to this paper. 
 
3. Sudano I*, Flammer AJ, Periat D, Enseleit F, Hermann M, Wolfrum M, Hirt 
A, Kaiser P, Hurlimann D, Neidhart M, Gay S, Nussberger J, Mocharla P, 
Landmesser U, Haile SR, Corti R, Vanhoutte PM, Lüscher TF, Noll G, 
Ruschitzka F. Acetaminophen increases Blood Pressure in Patients with 
Coronary Artery Disease. Circulation. 2010 Nov 2;122(18):1789-96 
 3 
Summary 
 
 The pathological elevation of arterial blood pressure is one of the most 
important cardiovascular risk factors deserving a careful monitoring by patients 
and medical doctors. 
 
 Dysfunctional vessels and blood pressure values are strictly related in 
a dangerous vicious circle. 
 
 When prescribing drugs we should be sure we should keep in mind 
that beyond their primary effect they could have positive as well negative 
ancillary effects. Using antihypertensive drugs we should consider not only the 
blood pressure effect but also check if they modified vascular function; 
cardiovascular drugs may have beneficial effect in patients with non-
cardiovascular disease and last but not least non-cardiovascular drugs may 
influence the cardiovascular risk profile of our patients. 
 
1. Chronic Treatment With Long-Acting Nifedipine Reduces 
Vasoconstriction to Endothelin-1 in Essential Hypertension 
In 9 healthy subjects (normotensive subjects,  age: 48.3+/-7.6 years; blood 
pressure: 118+/-8.6/69+/-5.4 mm Hg) and 21 patients with essential 
hypertension (age: 50.0+/-7.8 years; blood pressure: 164.4+/-5.4/103.8+/-4.4 
mm Hg), we studied forearm blood flow and its modification induced by 
intrabrachial administration of endothelin-1, phenylephrine, acetylcholine, and 
sodium nitroprusside at baseline and after 24 weeks of treatment with a 
nifedipine gastrointestinal therapeutic system (30 to 60 mg per day). At 
baseline, the first dose of endothelin-1 (0.5 microg/100 mL of forearm tissue 
per minute) caused a slight vasodilatation in normotensives but not in 
hypertensive subjects, whereas the following higher doses caused a 
comparable dose-dependent vasoconstriction in hypertensives and 
normotensives. The effect of acetylcholine was significantly reduced in 
patients with essential hypertension as compared with normotensive subjects. 
In contrast, sodium nitroprusside and phenylephrine had similar effects in both 
groups. After chronic treatment with the nifedipine gastrointestinal therapeutic 
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system, the vasoconstrictor effect induced by both endothelin-1 and 
phenylephrine was significantly blunted, whereas the response to 
acetylcholine was significantly increased and the vasodilation to sodium 
nitroprusside unchanged. In conclusion, this study showed as in patients with 
essential hypertension, chronic treatment with a long-acting dihydropyridine 
calcium antagonist not only exhibits a blood pressure-lowering effect but also 
reduces the vasoconstriction induced by endothelin-1 and improves 
endothelium-dependent vasodilation. Those vasculoprotective effects may 
importantly contribute to a reduction in major clinical events seen during 
treatment with these compounds.1 
 
2. Angiotensin converting enzyme Inhibition improves vascular 
function in rheumatoid arthritis 
 
Patients with rheumatoid arthritis are characterized by increased 
cardiovascular risk. Angiotensin-converting enzyme inhibitors are proven to 
exert a beneficial effect in patients with atherosclerotic vascular disease. In 
view of the similarities between atherosclerosis and rheumatoid arthritis, we 
planned to evaluate the impact of treatment with ramipril on endothelial 
function as well as on markers of inflammation and oxidative stress in 
normotensive patients with rheumatoid arthritis. 
We included eleven patients with rheumatoid arthritis in this randomized, 
double-blind, crossover study. The patients received ramipril in an uptitration 
design (2.5 to 10 mg) for 8 weeks followed by placebo, or vice versa, on top of 
standard antiinflammatory therapy. Endothelial function assessed by flow-
mediated dilation of the brachial artery, markers of inflammation and oxidative 
stress, and disease activity were investigated at baseline and after each 
treatment period. 
Endothelial function assessed by flow-mediated dilation increased from 
2.85±1.49% to 4.00±1.81% (P=0.017) after 8 weeks of therapy with ramipril 
but did not change with placebo (from 2.85±1.49% to 2.84±2.47%; P=0.88). 
Although systolic blood pressure and heart rate remained unaltered, diastolic 
blood pressure decreased slightly from 78±7 to 74±6 mm Hg (P=0.03). Tumor 
necrosis factor-a showed a significant inverse correlation with flow-mediated 
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dilation (r=0.408, P=0.02), and CD40 significantly decreased after ramipril 
therapy (P=0.049). 
In conclusions we demonstrated as angiotensin-converting enzyme inhibition 
with 10 mg/d ramipril for 8 weeks on top of current antiinflammatory treatment 
markedly improved endothelial function in patients with rheumatoid arthritis. 
This finding suggests that angiotensin-converting enzyme inhibition may 
provide a novel strategy to prevent cardiovascular events in these patients. 2 
 
3. Acetaminophen increases Blood Pressure in Patients with Coronary 
Artery Disease 
In 33 patients with coronary artery disease we evaluated 24-hour ambulatory 
blood pressure, heart rate, endothelium-dependent and -independent 
vasodilatation, platelet function, endothelial progenitor cells, markers of the 
renin-angiotensin system, inflammation, and oxidative stress before and after 
2-week treatment with paracetamol (1 g TID) and placebo on top of standard 
cardiovascular therapy. Treatment with paracetamol resulted in a significant 
increase in mean systolic (from 122.4±11.9 to 125.3±12.0 mm Hg P=0.02 
versus placebo) and diastolic (from 73.2±6.9 to 75.4±7.9 mm Hg P=0.02 
versus placebo) ambulatory blood pressures. On the other hand, heart rate, 
endothelial function, early endothelial progenitor cells, and platelet function did 
not change. 
Our data demonstrate for the first time that paracetamol similarly to other drug 
used to reduce pain, induces a significant increase in ambulatory blood 
pressure in patients with coronary artery disease.3  
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“As to diseases, make a habit of two things to help, or at least, to do no harm.”  
Hippokrates 
 
1.0 Introduction 
 
 Blood flows from heart through the arteries, capillaries, and finally veins 
back to the heart. The blood pressure is the force that allows this vital flow. 
  The importance of blood pressure is underlined by the existence of an 
extremely precise and complex control system involving the autonomic 
nervous system, the kidney and several hormones.  
 The arteries and the veins are also important for the blood pressure 
control. Dysfunctional vessels lead to an increase in blood pressure starting a 
dangerous vicious circle. 
 
 The pathological elevation of arterial blood pressure is a „silent killer“ 
leading to cardiovascular diseases. In 2008 in Switzerland 22’321 persons 
died for cardiovascular diseases and arterial hypertension is one of the most 
important cardiovascular risk factor.4 
 
 In a general swiss population 23% of men and 21% of women were aware 
of being hypertensive. At the age of 55-64 years this prevalence rise up to 
39% (men) and 32% (women) and at the age of 65-74 years 44% of the men 
and 46% of the women were hypertensive. Many persons are indeed 
hypertensive but they are not aware of this problem.5 
 
 Blood pressure should be regularly checked and if elevated, should be 
reduced by life-style changes or drug treatment. Some antihypertensive drugs 
“just” reduce blood pressure while others seems to have additional beneficial 
effect beyond lowering blood pressure.  
 From the other side, we should keep in mind that some useful drugs may 
induce an elevation of blood pressure. 
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1.1 Clinical significance of measuring blood pressure and evaluating 
vessel function 
 
Blood pressure values are an important component of the total 
cardiovascular risk defined by the presence of different risk factors, organ 
damage and disease. Several studies have shown that a blood pressure 
higher than 140/90 mmHg is associated with increased cardiovascular 
morbidity and mortality and reducing blood pressure values under this 
threshold by life-style modification or drug treatment significantly reduces fatal 
and non-fatal cardiovascular events. 
 
An impaired vessel function, measured as a reduced endothelial 
function or an increased arterial stiffness, was found to be associated with 
arterial hypertension 6, 7 as well as with other cardiovascular risk factors.6, 8-10 
Moreover, the presence of this vascular impairment has a negative prognostic 
value in patients with cardiovascular risk factors or cardiovascular diseases.6, 
8, 11 
 
1.2 Methods used to evaluate endothelial function 
 
 The acknowledgment of the central role played by the endothelium in 
the atherothrombotic process led to the development of a wide range of 
methods for assessing endothelial function in vivo. The aim was not only 
exploring the patho-physiologic mechanisms underlying atherothrombosis but 
also using endothelial function as an early clinical marker of the disease and to 
assess the response to medical interventions. 
 
 The most used invasive methodologies include the evaluation of the 
coronary response to endothelial agonists/antagonists or to physical 
manoeuvres like cold pressure test and the evaluation of endothelial function 
in the microcirculation of the forearm by strain gauge plethysmography.12 The 
invasive methods allow us to examine the potential mechanisms underlying 
endothelial dysfunction and the improvement of endothelial function induced 
by pharmacological and non-pharmacological interventions. At the present 
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time the flow-mediated dilatation of the brachial artery is considered the gold 
standard within the non-invasive methods for evaluating endothelial function in 
vivo.8 Other methods are measurements of the changes in augmentation 
index or in reflective index induced by drugs such as beta2-agonists or the 
pulse amplitude tonometry.8, 12 
 
Endothelial function in patients with arterial hypertension 
 
 The vascular endothelium plays a fundamental role in modulating 
vascular tone and structure. Physiological production of vascular relaxing 
factors, including “nitric oxide”(NO), “prostacyclin” and “hyperpolarizing 
relaxing factor” protect the vessel wall by antagonizing the initial pathological 
steps of atherosclerosis and thrombosis.(Figure 1)  At the same time the 
endothelium produces also vasoconstrictors such as endothelin-1, 
prostanoids.(Figure 1) Alterations in endothelial function are detectable in 
experimental and human hypertension, however, these changes and the 
underlying mechanisms are not uniform in different models of hypertension nor 
in different vascular beds.13 
  
Figure 1: Vasoactive substances produced by the endothelial cells: ACh: 
acetylcholine; 5HT: serotonin; ET1: Endothelin1, BK: bradykinin; AI: 
Angiotensin I, AII: Angiotensin II, ACE: Angiotensin Converting Enzyme, TGF-
β1: Transforming Growth Factor-β1, Thr: Thrombin, AT1: Angiotensin 
Receptor1, bET: big Endothelin, ECE: Endothelin Converting Enzyme, NO: 
nitric oxide, NOS: nitric oxide synthase; L-Arg: L-Arginine, ETA: Endothelin-
Receptor-A, ETB: Endothelin-Receptor-B, PGH2: ProstaglandinH2: PGI2: 
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Prostacyclin, THB4: Tetrahydrobiopterin, ADMA: asymmetric dimethylarginine; 
TXA: thromboxane; NAD(P)HOx: NAD(P) Oxidase. 
 
 In human hypertension the mechanisms appear to be different at 
various stages of the hypertensive process and somehow endothelial 
dysfunction precedes the development of hypertension as normotensive 
offspring of hypertensive parents exhibit impaired endothelium-dependent 
vasodilatation to acetylcholine. Moreover, in patients with manifest 
hypertension and in normotensive offspring, vasoconstriction due to inhibition 
of NO synthesis is decreased, indicating a reduced basal NO bioavailability.13 
Although the haemodynamic factor plays an important role, the reduction of 
blood pressure per se does not induce a modification in endothelial function in 
hypertensive patients.14, 15 
 
2.0 Effect of antihypertensive drugs on endothelial function 
 
 With regard to the endothelial function different effect can be exerted 
by different antihypertensives. Calcium-antagonist such as nifedipine may 
improve endothelial function in the coronary circulation16 and in the forearm 
circulation of hypertensive patients.1 Moreover, it is of note that in 
normotensive subjects, where the production of nitric oxide is preserved, the 
effect of endothelin-1 in maintaining vascular tone is very modest, whereas in 
hypertensive patients, where nitric oxide bioavailability is reduced, a 
vasoconstrictor component of endothelin-1 seems to be much more evident. 
Interestingly,  nifedipine non only increases the vasodilating response to 
acetylcholine but also reduces the vasoconstriction by endothelin-1 in 
essential hypertensive patients.(Figure 2)1  
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Figure 2 Forearm blood flow (FBF) responses (D%) to Endothelin(ET)-1 and 
phenylephrine in normotensive subjects (n=9, ), and hypertensive patients 
(n=21) before () and after () treatment with nifedipine GITS. *P<0.05 or 
less for normotensive subjects vs hypertensive patients; P<0.05 or less for 
hypertensive patients before vs after treatment. 
 
 Not only calcium-antagonists but also antagonists of the renin-
angiotensin system may positively influence endothelial function in patients 
with arterial hypertension.13 However, the beneficial effect of this 
pharmacological class seems to be not only limited to patients with arterial 
hypertension.  
 
Patients with rheumatoid arthritis are characterized by high 
cardiovascular risk, possibly due to inflammation and these patients are 
characterized by impaired endothelial function.17, 18 
 
 Indeed, we recently demonstrated that the angiotensin-converting 
enzyme inhibitor, ramipril, improves endothelial function in patients with 
rheumatoid arthritis and normal blood pressure values.(Figure 3)2 
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Figure 3: Endothelial function measured as flow-mediated vasodilatation 
(FMD) of the brachial artery at baseline and after treatment with ramipril and 
placebo. Asterisks indicate a statistically significant difference (P<0.05) 
ramipril vs baseline. 
 
3.0 Effect of non-cardiovascular drugs on cardiovascular system 
 
 The Food and Drug Administration warns patients with cardiovascular 
disease to use Cyclooxygenase-2 (COX-2) selective inhibitors and non-
selective non-steroidal anti-inflammatory drugs (NSAIDs) in view of the 
potential of these agents to increase adverse cardiovascular outcomes. 
Nevertheless, millions of patients worldwide require pain-relieving therapy to 
maintain an acceptable quality of life, the uncertainty around the 
cardiovascular safety of those drugs leaves practitioners and patients with 
difficult management decisions.3 
 
Current guidelines recommend paracetamol as the first-line analgesic of 
choice for the management of chronic pain despite weaker analgesic potency 
on the assumption of its greater cardiovascular safety, particularly in patients 
at high cardiovascular risk or with established cardiovascular disease.19 
 
One of the most commonly used drugs worldwide, a major ingredient in 
numerous cold and flu medications and commonly used even in children and 
pregnant women, paracetamol was considered safe, within therapeutic doses. 
3, 19 
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The link between paracetamol and cardiovascular risk factors or events 
were explored by a limited number of observational 20-22 and interventional 
studies23-25 and the results are so far inconsistent. 
In a recently published, randomized, placebo-controlled, cross-over trial we 
assessed 24-hour blood pressure and endothelial function in 33 patients with 
stable coronary artery diseases before and after treatment with paracetamol 
3gr/day or placebo. This study for the first time demonstrates a significant 
increase in ambulatory blood pressure in patients with coronary artery disease 
treated with paracetamol. (Figure 4)3 
 
 
Figure 4: Difference in mean 24-hour ambulatory blood pressure (Delta BP, 
mm Hg) between baseline and treatment with paracetamol (grey bars) and 
placebo (open bars). Data are presented as mean±SEM. Asterisks indicate a 
statistically significant difference (P<0.05) paracetamol versus placebo. 
 
 
The vascular function did not significantly worsen during the two weeks of 
treatment with paracetamol. 
Therefore, the results of the present study question the presumption of 
acetaminophen's cardiovascular safety suggesting that the effect of 
paracetamol on cardiovascular morbidity and mortality deserve more attention 
by the scientific community. 
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4.0 Conclusions 
 
 Blood pressure and vascular function are two important component of 
the global cardiovascular risk. 
 
 We use drug everyday, we should keep in mind that drugs beyond 
their primary effect may have some positive effects as well as side effects. 
 
 The effect of cardiovascular and non-cardiovascular drugs on blood 
pressure and vascular function is therefore an important clinical and research 
target aiming to a better protection of our patients. 
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